Isomorphic Labs' chief executive, Sir Demis Hassabis, delivering his Nobel Prize lecture in 2024. Alphabet-backed start-up Isomorphic Labs has added to the lustre attached to its AI-powered drug ...
Monday - Friday, 08:00 - 11:00 CET | 14:00 - 17:00 HK/SG Max Jaderberg, President of Isomorphic Labs, speaks to CNBC's Ritika Gupta at London Tech Week to discuss the advancement of AI in medicine Got ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Isomorphic Labs, an AI drug discovery and development company, raised $2.1 billion in a Series B funding round led by Thrive Capital. The raise was also backed by existing investors Alphabet and GV ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Demis Hassabis, CEO of Isomorphic and Google DeepMind Isomorphic, which formed as an ...
Isomorphic Labs, an artificial intelligence-driven drug discovery company, said on Wednesday it has raised $2.1 billion in its latest funding round led by existing investor Thrive Capital. The funding ...
The organisation plans to use the investment as a means of accelerating the application of its AI model at scale. AI-powered drug design and development company Isomorphic Labs has announced a raise ...
Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting their money behind more mature and de-risked assets. Alphabet’s AI-forward ...
May 12 (Reuters) - Isomorphic Labs, an artificial intelligence-driven drug discovery company, said on Wednesday it has raised $2.1 billion in its latest funding round led by existing investor Thrive ...
Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline. LONDON, May 12, 2026 /PRNewswire/ -- ...
Ruth Porat, President and Chief Investment Officer of Alphabet and Google, said Isomorphic has “already made extraordinary progress in harnessing AI to accelerate drug discovery.” (iStock/Getty Images ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results